StockData
Axsome Therapeutics, Inc. logo

Axsome Therapeutics, Inc. (AXSM) stock

AXSMNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 2, 2026Score 8/30
$134.00−1.95 (-1.43%)

Close on Nov 18, 2026Market cap $7.02BP/E –Yield –

Axsome Therapeutics revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Axsome Therapeutics's revenue for the twelve months ending Jun 30, 2026 was $776.57M, up 56.9% year over year. For fiscal 2025 it was $638.50M, up 65.5% from the year before.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025$638.50M+65.5%
FY2024Dec 31, 2024$385.69M+42.5%
FY2023Dec 31, 2023$270.60M+440.8%
FY2022Dec 31, 2022$50.04M–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$218.38M+45.5%
Q1 FY2026Mar 31, 2026$191.20M+57.4%
Q4 FY2025Dec 31, 2025$196.00M+65.0%
Q3 FY2025Sep 30, 2025$170.99M+63.2%
Q2 FY2025Jun 30, 2025$150.04M+72.1%
Q1 FY2025Mar 31, 2025$121.46M+62.0%
Q4 FY2024Dec 31, 2024$118.77M+66.0%
Q3 FY2024Sep 30, 2024$104.76M+81.3%
Q2 FY2024Jun 30, 2024$87.17M+86.7%
Q1 FY2024Mar 31, 2024$75.00M-20.7%
Q4 FY2023Dec 31, 2023$71.53M+193.5%
Q3 FY2023Sep 30, 2023$57.79M+243.1%
Q2 FY2023Jun 30, 2023$46.70M+429.5%
Q1 FY2023Mar 31, 2023$94.58M–
Q4 FY2022Dec 31, 2022$24.37M–
Q3 FY2022Sep 30, 2022$16.85M–
Q2 FY2022Jun 30, 2022$8.82M–
Q3 FY2021Sep 30, 2021$0–
Q2 FY2021Jun 30, 2021$0–

More Axsome Therapeutics figures

See a number that looks wrong?